Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study

Abstract LDL-apheresis (LDLa) efficacy in the treatment of symptomatic HyperLp(a)lipoproteinemia -HyperLp(a)- has been studied in a multicentre trial. After 3.1±2.7 years of weekly and biweekly treatment, the data from 19 patients (males:12; females:7; aged 53.8±9.3 years; mean body mass index: 24.6±2.3 Kg/m 2 ) were evaluated. Data were collected using the same questionnaire shared by 5 participating centres. A total of 2331 procedures were performed. A mean of 3593.7±800.3 ml of plasma or 8115.3±2150.1 ml of blood, depending upon the technique used (H.E.L.P., D.A.LI., Dextransulphate, Lipocollect 200), was regularly treated on average every 10.1±2.6 days. Baseline mean Lp(a) levels were 172.3±153.8 mg/dL. The mean pre-/post-apheresis Lp(a) levels decreased from 124.5±107.2 mg/dL (p